Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 591

1.

[JETALS: The Japanese Early-stage Trial of high dose methylcobalamin for ALS].

Izumi Y, Oki R, Kuwabara S, Kaji R.

Brain Nerve. 2019 Nov;71(11):1261-1269. doi: 10.11477/mf.1416201436. Japanese.

PMID:
31722312
2.

Texture analysis of sonographic muscle images can distinguish myopathic conditions.

Nodera H, Sogawa K, Takamatsu N, Hashiguchi S, Saito M, Mori A, Osaki Y, Izumi Y, Kaji R.

J Med Invest. 2019;66(3.4):237-247. doi: 10.2152/jmi.66.237.

3.

Optical coherent transients in 167Er3+ at telecom-band wavelength.

Hiraishi M, IJspeert M, Tawara T, Adachi S, Kaji R, Omi H, Gotoh H.

Opt Lett. 2019 Oct 15;44(20):4933-4936. doi: 10.1364/OL.44.004933.

PMID:
31613232
4.

Marker-assisted selection in rice breeding programs in Hokkaido.

Fujino K, Hirayama Y, Kaji R.

Breed Sci. 2019 Sep;69(3):383-392. doi: 10.1270/jsbbs.19062. Epub 2019 Jul 24. Review.

5.

Measurement of axonal excitability: Consensus guidelines.

Kiernan MC, Bostock H, Park SB, Kaji R, Krarup C, Krishnan AV, Kuwabara S, Lin CS, Misawa S, Moldovan M, Sung J, Vucic S, Wainger BJ, Waxman S, Burke D.

Clin Neurophysiol. 2019 Aug 2. pii: S1388-2457(19)31170-8. doi: 10.1016/j.clinph.2019.07.023. [Epub ahead of print] Review.

6.

Lesser motor disability in adulthood: A ten-year follow-up of a dyskinetic patient with ADCY5 mutation.

Kawarai T, Orlacchio A, Kaji R.

J Neurol Sci. 2019 Oct 15;405:116383. doi: 10.1016/j.jns.2019.07.001. Epub 2019 Jul 31. No abstract available.

PMID:
31422281
7.

Co-morbidity of progressive supranuclear palsy and amyotrophic lateral sclerosis: a clinical-pathological case report.

Fujita K, Matsubara T, Miyamoto R, Sumikura H, Takeuchi T, Maruyama Saladini K, Kawarai T, Nodera H, Udaka F, Kume K, Morino H, Kawakami H, Hasegawa M, Kaji R, Murayama S, Izumi Y.

BMC Neurol. 2019 Jul 18;19(1):168. doi: 10.1186/s12883-019-1402-7.

8.

The updated retrospective questionnaire study of sporadic inclusion body myositis in Japan.

Suzuki N, Mori-Yoshimura M, Yamashita S, Nakano S, Murata KY, Mori M, Inamori Y, Matsui N, Kimura E, Kusaka H, Kondo T, Ito H, Higuchi I, Hashiguchi A, Nodera H, Kaji R, Tateyama M, Izumi R, Ono H, Kato M, Warita H, Takahashi T, Nishino I, Aoki M.

Orphanet J Rare Dis. 2019 Jun 26;14(1):155. doi: 10.1186/s13023-019-1122-5.

9.

"One line": A method for differential diagnosis of parkinsonian syndromes.

Sako W, Abe T, Haji S, Murakami N, Osaki Y, Izumi Y, Harada M, Kaji R.

Acta Neurol Scand. 2019 Sep;140(3):229-235. doi: 10.1111/ane.13136. Epub 2019 Jun 21.

PMID:
31225648
10.

Global burden of neurological diseases highlights stroke.

Kaji R.

Nat Rev Neurol. 2019 Jul;15(7):371-372. doi: 10.1038/s41582-019-0208-y. No abstract available.

PMID:
31152152
11.

PMP22-related disease: A novel splice site acceptor variant and intrafamilial phenotype variability.

Kawarai T, Yamazaki H, Miyamoto R, Takamatsu N, Mori A, Osaki Y, Orlacchio A, Nodera H, Hashiguchi A, Higuchi Y, Yoshimura A, Takashima H, Kaji R.

Neuromuscul Disord. 2019 Jun;29(6):422-426. doi: 10.1016/j.nmd.2019.03.010. Epub 2019 Mar 28.

PMID:
31122831
12.

Potential Utility of 123I-MIBG Scintigraphy as a Predictor of Falls in Parkinson's Disease.

Murakami N, Sako W, Haji S, Furukawa T, Otomi Y, Otsuka H, Izumi Y, Harada M, Kaji R.

Front Neurol. 2019 Apr 12;10:376. doi: 10.3389/fneur.2019.00376. eCollection 2019.

13.

Deterministic-tractography-based approach for diagnosis and disease monitoring of amyotrophic lateral sclerosis.

Sako W, Abe T, Izumi Y, Harada M, Kaji R.

Clin Neurol Neurosurg. 2019 Jun;181:73-75. doi: 10.1016/j.clineuro.2019.04.015. Epub 2019 Apr 15.

PMID:
31009854
14.

Differences in the intra-cerebellar connections and graph theoretical measures between Parkinson's disease and multiple system atrophy.

Sako W, Abe T, Furukawa T, Oki R, Haji S, Murakami N, Izumi Y, Harada M, Kaji R.

J Neurol Sci. 2019 May 15;400:129-134. doi: 10.1016/j.jns.2019.03.022. Epub 2019 Mar 25.

PMID:
30928779
15.

Deep learning for waveform identification of resting needle electromyography signals.

Nodera H, Osaki Y, Yamazaki H, Mori A, Izumi Y, Kaji R.

Clin Neurophysiol. 2019 May;130(5):617-623. doi: 10.1016/j.clinph.2019.01.024. Epub 2019 Feb 23.

PMID:
30870796
16.

MiR-33a is a therapeutic target in SPG4-related hereditary spastic paraplegia human neurons.

Nakazeki F, Tsuge I, Horie T, Imamura K, Tsukita K, Hotta A, Baba O, Kuwabara Y, Nishino T, Nakao T, Nishiga M, Nishi H, Nakashima Y, Ide Y, Koyama S, Kimura M, Tsuji S, Naitoh M, Suzuki S, Izumi Y, Kawarai T, Kaji R, Kimura T, Inoue H, Ono K.

Clin Sci (Lond). 2019 Feb 22;133(4):583-595. doi: 10.1042/CS20180980. Print 2019 Feb 28.

PMID:
30777884
17.

Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II/III randomised controlled study.

Kaji R, Imai T, Iwasaki Y, Okamoto K, Nakagawa M, Ohashi Y, Takase T, Hanada T, Shimizu H, Tashiro K, Kuzuhara S.

J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):451-457. doi: 10.1136/jnnp-2018-319294. Epub 2019 Jan 13.

18.

Distinct Incidence of Takotsubo Syndrome Between Amyotrophic Lateral Sclerosis and Synucleinopathies: A Cohort Study.

Izumi Y, Miyamoto R, Fujita K, Yamamoto Y, Yamada H, Matsubara T, Unai Y, Tsukamoto A, Takamatsu N, Nodera H, Hayashi S, Oda M, Mori A, Nishida Y, Watanabe S, Ogawa H, Uehara H, Murayama S, Sata M, Kaji R.

Front Neurol. 2018 Dec 13;9:1099. doi: 10.3389/fneur.2018.01099. eCollection 2018.

19.

The Japanese Early-Stage Trial of High-Dose Methylcobalamin for Amyotrophic Lateral Sclerosis (JETALS): Protocol for a Randomized Controlled Trial.

Oki R, Izumi Y, Nodera H, Sato Y, Nokihara H, Kanai K, Sonoo M, Urushitani M, Nishinaka K, Atsuta N, Kohara N, Shimizu T, Kikuchi H, Oda M, Ikeda K, Nagai M, Komai K, Kojima Y, Kuzume D, Isose S, Shimohama S, Abe K, Ito H, Noda K, Ishihara T, Morita M, Shimohata T, Teramukai S, Kagimura T, Noma K, Yanagawa H, Kuwabara S, Kaji R; JETALS.

JMIR Res Protoc. 2018 Dec 21;7(12):e12046. doi: 10.2196/12046.

20.

Increased IP-10 production by blood-nerve barrier in multifocal acquired demyelinating sensory and motor neuropathy and multifocal motor neuropathy.

Shimizu F, Oishi M, Sawai S, Beppu M, Misawa S, Matsui N, Miyashiro A, Maeda T, Takeshita Y, Nishihara H, Sano Y, Sato R, Kaji R, Kuwabara S, Kanda T.

J Neurol Neurosurg Psychiatry. 2019 Apr;90(4):444-450. doi: 10.1136/jnnp-2018-319270. Epub 2018 Dec 6.

PMID:
30523038
21.

Amyotrophic lateral sclerosis of long clinical course clinically presenting with progressive muscular atrophy.

Matsubara T, Oda M, Takahashi T, Watanabe C, Tachiyama Y, Morino H, Kawakami H, Kaji R, Maruyama H, Murayama S, Izumi Y.

Neuropathology. 2019 Feb;39(1):47-53. doi: 10.1111/neup.12523. Epub 2018 Dec 3.

PMID:
30511354
22.

Turning on the Left Side Electrode Changed Depressive State to Manic State in a Parkinson's Disease Patient Who Received Bilateral Subthalamic Nucleus Deep Brain Stimulation: A Case Report.

Kinoshita M, Nakataki M, Morigaki R, Sumitani S, Goto S, Kaji R, Ohmori T.

Clin Psychopharmacol Neurosci. 2018 Nov 30;16(4):494-496. doi: 10.9758/cpn.2018.16.4.494.

23.

Does afatinib plus bevacizumab combination therapy induce positive conversion of T790M in previously-negative patients?

Hata A, Katakami N, Kaji R, Yokoyama T, Kaneda T, Tamiya M, Inoue T, Kimura H, Yano Y, Tamura D, Morita S, Negoro S; HANSHIN Oncology Group.

Oncotarget. 2018 Oct 5;9(78):34765-34771. doi: 10.18632/oncotarget.26192. eCollection 2018 Oct 5.

24.

Classification of needle-EMG resting potentials by machine learning.

Nodera H, Osaki Y, Yamazaki H, Mori A, Izumi Y, Kaji R.

Muscle Nerve. 2019 Feb;59(2):224-228. doi: 10.1002/mus.26363. Epub 2018 Dec 18.

PMID:
30353953
25.

Compound heterozygote mutations in the SIGMAR1 gene in an oldest-old patient with amyotrophic lateral sclerosis.

Izumi Y, Morino H, Miyamoto R, Matsuda Y, Ohsawa R, Kurashige T, Shimatani Y, Kaji R, Kawakami H.

Geriatr Gerontol Int. 2018 Oct;18(10):1519-1520. doi: 10.1111/ggi.13506. No abstract available.

PMID:
30311446
26.

Age-dependent texture features in skeletal muscle ultrasonography.

Nodera H, Sogawa K, Takamatsu N, Mori A, Yamazaki H, Izumi Y, Kaji R.

J Med Invest. 2018;65(3.4):274-279. doi: 10.2152/jmi.65.274.

27.

Comparison of efficacy and toxicity between botulinum toxin subtypes A1 and A2 in cynomolgus macaques.

Torii Y, Sasaki M, Shin MC, Akaike N, Kaji R.

Toxicon. 2018 Oct;153:114-119. doi: 10.1016/j.toxicon.2018.08.017. Epub 2018 Sep 5.

PMID:
30193802
28.

Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study).

Hata A, Katakami N, Kaji R, Yokoyama T, Kaneda T, Tamiya M, Inoue T, Kimura H, Yano Y, Tamura D, Morita S, Negoro S, The Hanshin Oncology Group F.

Cancer. 2018 Oct 1;124(19):3830-3838. doi: 10.1002/cncr.31678. Epub 2018 Sep 7.

29.

An LC-MS/MS Method for Absolute Quantification of Nivolumab in Human Plasma: Application to Clinical Therapeutic Drug Monitoring.

Irie K, Okada A, Yamasaki Y, Kokan C, Hata A, Kaji R, Fukushima K, Sugioka N, Okada Y, Katakami N, Fukushima S.

Ther Drug Monit. 2018 Dec;40(6):716-724. doi: 10.1097/FTD.0000000000000558.

PMID:
30048380
30.

CSF cystatin C and diffusion tensor imaging parameters as biomarkers of upper motor neuron degeneration in amyotrophic lateral sclerosis.

Nakane S, Fujita K, Azuma S, Urushihara R, Kamada M, Harada M, Izumi Y, Kaji R.

Clin Neurol Neurosurg. 2018 Sep;172:162-168. doi: 10.1016/j.clineuro.2018.07.008. Epub 2018 Jul 10.

PMID:
30016754
31.

Docetaxel plus ramucirumab with primary prophylactic pegylated-granulocyte-colony stimulating factor for pretreated non-small cell lung cancer.

Hata A, Harada D, Okuda C, Kaji R, Masuda Y, Takechi Y, Kozuki T, Nogami N, Katakami N.

Oncotarget. 2018 Jun 12;9(45):27789-27796. doi: 10.18632/oncotarget.25578. eCollection 2018 Jun 12.

32.

Dural arteriovenous fistula in the superior orbital fissure: A case report.

Yamamoto Y, Yamamoto N, Satomi J, Yamaguchi I, Korai M, Kanematsu Y, Takagi Y, Kaji R.

Surg Neurol Int. 2018 May 7;9:95. doi: 10.4103/sni.sni_46_18. eCollection 2018.

33.

Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib.

Sakanoue I, Hamakawa H, Kaji R, Imai Y, Katakami N, Takahashi Y.

J Thorac Dis. 2018 Mar;10(3):E170-E174. doi: 10.21037/jtd.2018.02.03.

34.

Development and validation of a method for gefitinib quantification in dried blood spots using liquid chromatography-tandem mass spectrometry: Application to finger-prick clinical blood samples of patients with non-small cell lung cancer.

Irie K, Shobu S, Hiratsuji S, Yamasaki Y, Nanjo S, Kokan C, Hata A, Kaji R, Masago K, Fujita S, Okada Y, Katakami N, Fukushima S.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jun 15;1087-1088:1-5. doi: 10.1016/j.jchromb.2018.04.027. Epub 2018 Apr 13.

PMID:
29689441
35.

Phenotype variability and allelic heterogeneity in KMT2B-Associated disease.

Kawarai T, Miyamoto R, Nakagawa E, Koichihara R, Sakamoto T, Mure H, Morigaki R, Koizumi H, Oki R, Montecchiani C, Caltagirone C, Orlacchio A, Hattori A, Mashimo H, Izumi Y, Mezaki T, Kumada S, Taniguchi M, Yokochi F, Saitoh S, Goto S, Kaji R.

Parkinsonism Relat Disord. 2018 Jul;52:55-61. doi: 10.1016/j.parkreldis.2018.03.022. Epub 2018 Apr 5.

PMID:
29653907
36.

Assessment of exposure risk of irinotecan and its active metabolite, SN-38, through perspiration during chemotherapy.

Irie K, Okada A, Masuda Y, Fukushima K, Sugioka N, Okuda C, Hata A, Kaji R, Okada Y, Katakami N, Fukushima S.

J Oncol Pharm Pract. 2019 Jun;25(4):865-868. doi: 10.1177/1078155218769136. Epub 2018 Apr 13.

PMID:
29651916
37.

Intravenous immunoglobulin for maintenance treatment of multifocal motor neuropathy: A multi-center, open-label, 52-week phase 3 trial.

Kuwabara S, Misawa S, Mori M, Iwai Y, Ochi K, Suzuki H, Nodera H, Tamaoka A, Iijima M, Toda T, Yoshikawa H, Kanda T, Sakamoto K, Kusunoki S, Sobue G, Kaji R; Glovenin-I MMN Study Group.

J Peripher Nerv Syst. 2018 Jun;23(2):115-119. doi: 10.1111/jns.12268. Epub 2018 Apr 24.

38.

[Stiff-Person Syndrome and Related Autoantibodies].

Matsui N, Tanaka K, Kaji R.

Brain Nerve. 2018 Apr;70(4):357-362. doi: 10.11477/mf.1416201008. Review. Japanese.

PMID:
29632283
39.

Atezolizumab in Japanese Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis of the Phase 3 OAK Study.

Hida T, Kaji R, Satouchi M, Ikeda N, Horiike A, Nokihara H, Seto T, Kawakami T, Nakagawa S, Kubo T.

Clin Lung Cancer. 2018 Jul;19(4):e405-e415. doi: 10.1016/j.cllc.2018.01.004. Epub 2018 Feb 1.

40.

Neurologic attack and dynamic perfusion abnormality in neuronal intranuclear inclusion disease.

Fujita K, Osaki Y, Miyamoto R, Shimatani Y, Abe T, Sumikura H, Murayama S, Izumi Y, Kaji R.

Neurol Clin Pract. 2017 Dec;7(6):e39-e42. doi: 10.1212/CPJ.0000000000000389. No abstract available.

41.

Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy.

Dressler D, Bhidayasiri R, Bohlega S, Chana P, Chien HF, Chung TM, Colosimo C, Ebke M, Fedoroff K, Frank B, Kaji R, Kanovsky P, Koçer S, Micheli F, Orlova O, Paus S, Pirtosek Z, Relja M, Rosales RL, Sagástegui-Rodríguez JA, Schoenle PW, Shahidi GA, Timerbaeva S, Walter U, Saberi FA.

J Neurol. 2018 Apr;265(4):856-862. doi: 10.1007/s00415-018-8759-1. Epub 2018 Feb 8.

PMID:
29423615
42.

Frequency and characteristics of the TBK1 gene variants in Japanese patients with sporadic amyotrophic lateral sclerosis.

Tohnai G, Nakamura R, Sone J, Nakatochi M, Yokoi D, Katsuno M, Watanabe H, Watanabe H, Ito M, Li Y, Izumi Y, Morita M, Taniguchi A, Kano O, Oda M, Kuwabara S, Abe K, Aiba I, Okamoto K, Mizoguchi K, Hasegawa K, Aoki M, Hattori N, Onodera O, Naruse H, Mitsui J, Takahashi Y, Goto J, Ishiura H, Morishita S, Yoshimura J, Doi K, Tsuji S, Nakashima K, Kaji R, Atsuta N, Sobue G; Japanese Consortium for Amyotrophic Lateral Sclerosis Research (JaCALS).

Neurobiol Aging. 2018 Apr;64:158.e15-158.e19. doi: 10.1016/j.neurobiolaging.2017.12.005. Epub 2017 Dec 11.

PMID:
29398122
43.

Short communication: Probiotic induction of interleukin-10 and interleukin-12 production by macrophages is modulated by co-stimulation with microbial components.

Kaji R, Kiyoshima-Shibata J, Tsujibe S, Nanno M, Shida K.

J Dairy Sci. 2018 Apr;101(4):2838-2841. doi: 10.3168/jds.2017-13868. Epub 2018 Feb 4.

44.

Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer.

Hata A, Katakami N, Nanjo S, Okuda C, Kaji R, Masago K, Fujita S, Yoshida H, Zama K, Imai Y, Hirata Y.

Oncotarget. 2017 Dec 1;8(69):113807-113816. doi: 10.18632/oncotarget.22837. eCollection 2017 Dec 26.

45.

Validation of the digital PCR system in tyrosine kinase inhibitor-resistant EGFR mutant non-small-cell lung cancer.

Masago K, Fujita S, Hata A, Okuda C, Yoshizumi Y, Kaji R, Katakami N, Hirata Y, Yatabe Y.

Pathol Int. 2018 Mar;68(3):167-173. doi: 10.1111/pin.12630. Epub 2018 Jan 17.

PMID:
29341374
46.

Guillain-Barré syndrome in a local area in Japan, 2006-2015: an epidemiological and clinical study of 108 patients.

Matsui N, Nodera H, Kuzume D, Iwasa N, Unai Y, Sakai W, Miyazaki Y, Yamazaki H, Osaki Y, Mori A, Furukawa T, Tsukamoto-Miyashiro A, Shimatani Y, Yamasaki M, Izumi Y, Kusunoki S, Arisawa K, Kaji R.

Eur J Neurol. 2018 May;25(5):718-724. doi: 10.1111/ene.13569. Epub 2018 Mar 1.

PMID:
29337417
47.

The effect of istradefylline for Parkinson's disease: A meta-analysis.

Sako W, Murakami N, Motohama K, Izumi Y, Kaji R.

Sci Rep. 2017 Dec 21;7(1):18018. doi: 10.1038/s41598-017-18339-1.

48.

Dural Arterivenous Fistula at the Cavernous Sinus Diagnosed by Arterial Spin-labeled Imaging.

Yamamoto N, Yamamoto Y, Izumi Y, Kaji R.

Intern Med. 2018 Apr 15;57(8):1163-1166. doi: 10.2169/internalmedicine.9315-17. Epub 2017 Dec 21.

49.

Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer.

Nanjo S, Hata A, Okuda C, Kaji R, Okada H, Tamura D, Irie K, Okada H, Fukushima S, Katakami N.

Br J Cancer. 2018 Jan;118(1):32-37. doi: 10.1038/bjc.2017.394. Epub 2017 Nov 30.

50.

iPSC-Based Compound Screening and In Vitro Trials Identify a Synergistic Anti-amyloid β Combination for Alzheimer's Disease.

Kondo T, Imamura K, Funayama M, Tsukita K, Miyake M, Ohta A, Woltjen K, Nakagawa M, Asada T, Arai T, Kawakatsu S, Izumi Y, Kaji R, Iwata N, Inoue H.

Cell Rep. 2017 Nov 21;21(8):2304-2312. doi: 10.1016/j.celrep.2017.10.109.

Supplemental Content

Support Center